AbbVie
ABBV Mega CapHealthcare · Drug Manufacturers - General
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
AbbVie en bref
AbbVie (ABBV) is currently trading at 217,57 € with a market capitalization of 384,4 Md €. The trailing P/E ratio stands at 70.89x, with a forward P/E of 15.45x. The 52-week range spans from 165,38 € to 231,90 €; the current price is 6.2% below the yearly high. Year-over-year revenue growth stands at +10.2%. The net profit margin stands at 9.8%.
💰 Dividende
AbbVie pays an annual dividend of 6,00 € per share, representing a yield of 2.76%. The payout ratio stands at 189.86%. The elevated payout ratio reflects a mature dividend policy.
📊 Avis des analystes
28 analystes évaluent AbbVie (ABBV) au consensus : Acheter. L'objectif de cours moyen est de 234,43 €, soit un potentiel de +7.75% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 173,40 € à 284,38 €.
AbbVie : la thèse d'investissement en détail
AbbVie (ABBV) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 10.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 290.4% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 72.79%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
A trailing P/E above 50 combined with revenue growth below 20% is a dangerous combination — the market is paying a steep growth multiple for what is, by the data, only moderately fast expansion. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
With a PEG ratio of 0.41, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The forward P/E of 15.45x is meaningfully below the trailing 70.89x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 72.79% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Rendement du dividende solide de 2.76%
- –Multiple de valorisation élevé (P/E 70.89x)
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy AbbVie?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news